Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,795 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Genetic Change Clear all

Conditions: Non Small Cell Lung Cancer
Interventions: HM61713; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 20 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 15
States / cities: Beverly Hills, California • Burbank, California • Los Angeles, California + 11 more

Conditions: Non Small Cell Lung Cancer, NSCLC, KRAS G12C
Interventions: Adagrasib, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: Ryan Gentzler, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Columbus, Ohio • Charlottesville, Virginia • Richmond, Virginia

Conditions: Weight Management, Diet Conditions, Dietary Recommendations, Overweight Management, Obesity
Interventions: Not listed
Lead sponsor: Interleukin Genetics, Inc.; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity and Obesity-related Medical Conditions, Diabetes, Atherosclerotic Disease, Heart Failure, MASH, Sarcopenia, Osteoporosis, Hyperparathyroidism, Hypoparathyroidism, Ischemic Heart Disease, Cystic Fibrosis (CF), Chronic Kidney Disease(CKD), Osteopenia, Cachexia
Interventions: Endothelial cell collection; Other
Lead sponsor: Bettina Mittendorfer; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer
Interventions: BYL719, Fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Solid Tumor
Interventions: Phase I Arm A, Phase I Arm B; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 12
States / cities: La Jolla, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Prader-Willi Syndrome, Excessive Daytime Sleepiness, Hyperphagia, Body Weight, Mood, Behavior
Interventions: Sham Light, Bright Light Therapy; Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 6 Years to 88 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Cystic Fibrosis
Interventions: VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 27
States / cities: Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more

Conditions: Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder, Acute Myeloid Leukemia, Minimal Residual Disease Persistence, Therapy-Related Acute Myeloid Leukemia
Interventions: Azacitidine, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: capmatinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • Fairfax, Virginia

Conditions: Malignant Melanoma
Interventions: Placebo, Vemurafenib, Cobimetinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 20
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Interventions: LP-184, Olaparib, Nivolumab & Ipilimumab; Drug
Lead sponsor: Lantern Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more

Conditions: Inflammatory Bowel Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Erlotinib, Alectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Fullerton, California • Orange, California + 14 more

Conditions: Cystic Fibrosis
Interventions: Behavioral Counseling and Exercise; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Recurrent Melanoma, Stage IA Melanoma, Stage IB Melanoma, Stage IIA Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
Interventions: HPV 16 E7:12-20, gp100:209-217(210M), laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 17 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2013
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions: AZD0022, Cetuximab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Fairfax, Virginia

Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Interventions: Sodium phenylbutyrate; Drug
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: 10 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine and Cedazuridine, Gilteritinib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prion Diseases
Interventions: blood draw; Other
Lead sponsor: University of Zurich; Other
Eligibility: 1 Year to 99 Years
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostatic Neoplasm, Prostate Cancer, BRCA2 Mutation, BRCA1 Mutation, ATM Gene Mutation, MMR Mutation, Lynch Syndrome, Genetic Predisposition to Disease
Interventions: Prostate cancer screening; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years and older · Male only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hunter Syndrome
Interventions: Elaprase for intravenous (IV) infusion; Drug
Lead sponsor: Shire; Industry
Eligibility: Up to 5 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
Interventions: Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Fulvestrant, Magnetic Resonance Imaging, Multigated Acquisition Scan; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 192
States / cities: Birmingham, Alabama • Kingman, Arizona • Arroyo Grande, California + 155 more

Search by objective public record fields.

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

A to Z Study Follow-up: Collection of DNA Data From Buccal Swabs

Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

Impact of Bright Light Therapy on Prader-Willi Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Study of LP-184 in Patients With Advanced Solid Tumors

Telomere Repair Gene Mutation in Inflammatory Bowel Disease

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis

Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD

Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

Prostate Cancer Genetic Risk Evaluation and Screening Study

Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)